← All trials
NCT05081102
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Aug 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Oct 18, 2021
- Last posted
- Oct 18, 2021
- Enrollment
- 288
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eurofarma Laboratorios S.A.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.